ZOFRAN 8 MG
ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) : 8 MG · DIN 02213575 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: CANCELLED POST MARKET
What is ZOFRAN?
ZOFRAN 8 MG contains ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) : 8 MG. It is listed in the Health Canada Drug Product Database under DIN 02213575, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 14-Mar-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZOFRAN used for?
Prevention of nausea and vomiting associated with emetogenic chemotherapy and radiotherapy; prevention and treatment of post-operative nausea and vomiting.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02213575 |
|---|---|
| Brand name | ZOFRAN |
| Generic / active ingredient | ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) : 8 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 8 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A04AA01 ONDANSETRON |
| AHFS class | 56:22.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 14-Mar-2017 |
| Original market date | 1991-12-30 00:00:00 |
How is it administered?
Adults: 8-16 mg IV or 8-16 mg orally depending on indication. Max IV dose 16 mg. Infuse IV over 15 mins. Hepatic impairment: max 8 mg/day. Follow specific guidelines for elderly to reduce cardiac risk.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (refers to section 11), but mentions stability of diluted solutions for up to 2-7 days depending on conditions.
How is it supplied?
Tablets: blister packs of 10. ODT: 2 x 5 unit dose blisters. Oral Solution: 50 mL bottles. Injection: 2 mL and 4 mL ampoules in boxes of 5.
Contraindications
Hypersensitivity to the drug or any components; concomitant use of apomorphine (due to risk of profound hypotension and loss of consciousness).
Warnings and precautions
Dose-dependent QTc prolongation; risk of Torsade de Pointes; myocardial ischemia and coronary artery spasm; serotonin syndrome; avoid in congenital long QT syndrome.
Is ONDANSETRON in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A04AA01 ONDANSETRON. 59 of 135 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACCEL-ONDANSETRON | 4 MG | TABLET | ACCEL PHARMA INC | MARKETED | DIN 02478927 |
| ACCEL-ONDANSETRON | 8 MG | TABLET | ACCEL PHARMA INC | MARKETED | DIN 02478935 |
| ACCEL-ONDANSETRON ODT | 4 MG | TABLET (ORALLY DISINTEGRATING) | ACCEL PHARMA INC | MARKETED | DIN 02535319 |
| ACCEL-ONDANSETRON ODT | 8 MG | TABLET (ORALLY DISINTEGRATING) | ACCEL PHARMA INC | MARKETED | DIN 02535327 |
| APO-ONDANSETRON | 4 MG | TABLET | APOTEX INC | MARKETED | DIN 02288184 |
| APO-ONDANSETRON | 4 MG / 5 ML | SOLUTION | APOTEX INC | MARKETED | DIN 02291967 |
| APO-ONDANSETRON | 8 MG | TABLET | APOTEX INC | MARKETED | DIN 02288192 |
| AURO-ONDANSETRON INJECTION | 2 MG | SOLUTION | AURO PHARMA INC | MARKETED | DIN 02491532 |
| AURO-ONDANSETRON INJECTION | 2 MG | SOLUTION | AURO PHARMA INC | MARKETED | DIN 02491524 |
| AURO-ONDANSETRON ODT | 4 MG | TABLET (ORALLY DISINTEGRATING) | AURO PHARMA INC | MARKETED | DIN 02511282 |
Who else supplies ONDANSETRON worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ONDANSETRON appears in 992 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.